A recap of AACR with highlights of liquid biopsy MRD, methylation, and whole genome CNV
The liquid biopsy landscape is changing rapidly. Predicine is advancing the clinical utility of liquid biopsy more broadly across the continuum of cancer care. We are innovating our liquid biopsy technology to detect a range of genomic signatures that will impact clinical care in the future.
During this webinar we will highlight Predicine’s liquid biopsy advancement in minimal residual disease (MRD), methylation, and low-pass whole genome detection of copy number variations (CNV), presented at AACR 2021. Come join us to learn more about where liquid is going!
Date: Wednesday, June 2, 2021
Time: 1:00 PM EDT / 10 AM PDT
Topics to be covered:
Title: AACR Recap: Updates in Liquid Biopsy
Date: Wednesday, June 2, 2021
Time: 1:00pm Eastern Standard Time
Duration: 40 minutes